ACB vs. GUD, OGI, CPH, CRDL, HLS, WEED, CRON, EXE, KSI, and FRX
Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Knight Therapeutics (GUD), Organigram (OGI), Cipher Pharmaceuticals (CPH), Cardiol Therapeutics (CRDL), HLS Therapeutics (HLS), Canopy Growth (WEED), Cronos Group (CRON), Extendicare (EXE), kneat.com (KSI), and Fennec Pharmaceuticals (FRX). These companies are all part of the "medical" sector.
Aurora Cannabis (TSE:ACB) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
7.1% of Aurora Cannabis shares are held by institutional investors. Comparatively, 13.7% of Knight Therapeutics shares are held by institutional investors. 46.4% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Knight Therapeutics had 5 more articles in the media than Aurora Cannabis. MarketBeat recorded 6 mentions for Knight Therapeutics and 1 mentions for Aurora Cannabis. Knight Therapeutics' average media sentiment score of 0.30 beat Aurora Cannabis' score of 0.20 indicating that Knight Therapeutics is being referred to more favorably in the news media.
Aurora Cannabis received 418 more outperform votes than Knight Therapeutics when rated by MarketBeat users. However, 74.83% of users gave Knight Therapeutics an outperform vote while only 63.16% of users gave Aurora Cannabis an outperform vote.
Aurora Cannabis has a net margin of 151.71% compared to Knight Therapeutics' net margin of -5.13%. Knight Therapeutics' return on equity of -2.14% beat Aurora Cannabis' return on equity.
Aurora Cannabis has higher earnings, but lower revenue than Knight Therapeutics. Knight Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
Aurora Cannabis currently has a consensus price target of C$2.26, suggesting a potential downside of 74.44%. Knight Therapeutics has a consensus price target of C$6.63, suggesting a potential upside of 12.05%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Knight Therapeutics is more favorable than Aurora Cannabis.
Aurora Cannabis has a beta of 2.93, suggesting that its stock price is 193% more volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.
Summary
Knight Therapeutics beats Aurora Cannabis on 13 of the 18 factors compared between the two stocks.
Get Aurora Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurora Cannabis Competitors List
Related Companies and Tools
